Standard BioTools Inc (NASDAQ: LAB) kicked off on Monday, down -5.19% from the previous trading day, before settling in for the closing price of $1.35. Over the past 52 weeks, LAB has traded in a range of $0.92-$2.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.61% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 55.47%. With a float of $367.76 million, this company’s outstanding shares have now reached $379.09 million.
In an organization with 818 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 47.04%, operating margin of -82.21%, and the pretax margin is -78.07%.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 3.18%, while institutional ownership is 72.28%. The most recent insider transaction that took place on May 23 ’25, was worth 1,344. In this transaction Chief Financial Officer of this company sold 1,428 shares at a rate of $0.94, taking the stock ownership to the 930,286 shares. Before that another transaction happened on May 23 ’25, when Company’s SVP & Chief Business Officer sold 13,217 for $0.94, making the entire transaction worth $12,437. This insider now owns 843,076 shares in total.
Standard BioTools Inc (LAB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 55.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 66.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Take a look at Standard BioTools Inc’s (LAB) current performance indicators. Last quarter, stock had a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.64 million. That was inferior than the volume of 1.83 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.36%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 53.73%, which indicates a significant increase from 45.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.27% in the past 14 days, which was higher than the 81.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1155, while its 200-day Moving Average is $1.4850. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.3133. Second resistance stands at $1.3467. The third major resistance level sits at $1.3633. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.2467. The third support level lies at $1.2133 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
The company with the Market Capitalisation of 486.17 million has total of 379,822K Shares Outstanding. Its annual sales at the moment are 174,430 K in contrast with the sum of -138,890 K annual income. Company’s last quarter sales were recorded 40,800 K and last quarter income was -26,030 K.
